Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glyxambi

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

- PMLiVE

FDA investigates pancreas risk of diabetes drugs

Products from Merck & Co, BMS, AZ, Novo Nordisk, Boehringer, Amylin and Takeda all involved

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

FDA explains draft Alzheimer’s guidance in NEJM editorial

Intends to relax requirements in patient function and cognition

- PMLiVE

Informatics to drive clinical trials in UK

Scotland’s chief scientist says NHS data can support medicines research

Astellas files diabetes drug ipragliflozin in Japan

Its SGLT2 inhibitor could beat AZ-BMS' rival Forxiga to debut in that market

- PMLiVE

ACC and Boehringer develop CME programme in China

Will focus on stroke prevention in atrial fibrillation

FDA smartphone regulation could stifle innovation

US House Republicans issue warning on guidance and call for more information

- PMLiVE

GSK submits albiglutide for European approval

If approved the diabetes drug will be launched as Eperzan

- PMLiVE

AZ loses Crestor patent battle in Australia

Follows challenge from Apotex

- PMLiVE

FDA approves J&J’s Bluetooth blood glucose monitor

Licenses iPhone, iPad and iPod Touch compatible monitoring system

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links